BMO Capital analyst Evan Seigerman assigned a Buy rating to Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $355.00. The company’s shares opened today at $302.98.
Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Mirati Therapeutics. According to TipRanks, Seigerman has an average return of 6.8% and a 53.19% success rate on recommended stocks.
Currently, the analyst consensus on Vertex Pharmaceuticals is a Moderate Buy with an average price target of $333.23, which is a 9.98% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $342.00 price target.
See the top stocks recommended by analysts >>
Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.33 billion and a net profit of $930.5 million. In comparison, last year the company earned a revenue of $1.98 billion and had a net profit of $851.9 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Read More on VRTX:
- Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports
- Vertex Pharmaceuticals price target raised to $296 from $293 at Piper Sandler
- Vertex Pharmaceuticals initiated with a Hold at Canaccord
- SVB Securities upgrades Vertex to Outperform, raises price target to $374
- Vertex Pharmaceuticals upgraded to Outperform at SVB Securities
